Ignite Creation Date:
2024-05-06 @ 7:10 AM
Last Modification Date:
2024-10-26 @ 11:45 AM
Study NCT ID:
NCT02487199
Status:
COMPLETED
Last Update Posted:
2017-12-04
First Post:
2015-06-29
Brief Title:
OmbitasvirParitaprevirRitonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus HCV Infection With Severe Kidney Impairment or End Stage Kidney Disease
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
An Open-Label Study to Evaluate the Safety and Efficacy of OmbitasvirParitaprevirRitonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus HCV Infection With Severe Renal Impairment or End-Stage Renal Disease RUBY-II
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the efficacy and safety of ombitasvirparitaprevirritonavir with or without dasabuvir in adults with hepatitis C virus HCV genotype 1a GT1a or genotype 4 GT4 infection and with severe kidney impairment or end-stage kidney disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2015-002012-33 | EUDRACT_NUMBER | None | None |